<DOC>
	<DOCNO>NCT00644605</DOCNO>
	<brief_summary>To evaluate effect three dose oral sildenafil ( 20 , 40 80 mg three time day [ TID ] ) exercise capacity , measure 6-Minute Walk test , well safety tolerability , 12 week treatment subject pulmonary arterial hypertension age 18 year . To investigate plasma concentration-effect relationship determine population pharmacokinetic ( PK ) parameter .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety 20 , 40 , 80mg Sildenafil Three Times Day Treatment Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Included patient primary pulmonary arterial hypertension , pulmonary hypertension secondary connective tissue disease , pulmonary hypertension surgical repair least 5 year previously ; mean pulmonary artery pressure great equal 25 mmHg pulmonary artery wedge pressure less equal 15 mmHg rest , via right heart catheterisation within 21 day prior randomisation ; baseline 6Minute Walk test distance 100 450 m. Subjects congenital heart disease , pulmonary hypertension due thromboembolism , HIV , chronic obstructive airway disease , congestive heart failure schistosomiasis ; subject significant ( ie &gt; 2+ ) valvular disease tricuspid regurgitation pulmonary regurgitation ; acutely decompensated heart failure within previous 30 day ; subject pulmonary hypertension secondary etiology specify inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>